- Home
- AEON vs MRKR Comparison
AEON vs MRKR Comparison
Compare AEON & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- MRKR
- Stock Information
- Founded
- AEON N/A
- MRKR N/A
- Country
- AEON United States
- MRKR United States
- Employees
- AEON N/A
- MRKR N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- MRKR Health Care
- Exchange
- AEON Nasdaq
- MRKR Nasdaq
- Market Cap
- AEON 10.6M
- MRKR 11.6M
- IPO Year
- AEON N/A
- MRKR N/A
- Fundamental
- Price
- AEON $0.89
- MRKR $0.94
- Analyst Decision
- AEON Strong Buy
- MRKR Strong Buy
- Analyst Count
- AEON 1
- MRKR 2
- Target Price
- AEON $7.20
- MRKR $10.25
- AVG Volume (30 Days)
- AEON 258.2K
- MRKR 153.3K
- Earning Date
- AEON 11-12-2025
- MRKR 11-14-2025
- Dividend Yield
- AEON N/A
- MRKR N/A
- EPS Growth
- AEON N/A
- MRKR N/A
- EPS
- AEON N/A
- MRKR N/A
- Revenue
- AEON N/A
- MRKR $5,388,071.00
- Revenue This Year
- AEON N/A
- MRKR N/A
- Revenue Next Year
- AEON N/A
- MRKR $9.06
- P/E Ratio
- AEON N/A
- MRKR N/A
- Revenue Growth
- AEON N/A
- MRKR 44.55
- 52 Week Low
- AEON $0.38
- MRKR $0.81
- 52 Week High
- AEON $64.80
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- AEON 48.00
- MRKR 47.18
- Support Level
- AEON $0.89
- MRKR $0.84
- Resistance Level
- AEON $1.09
- MRKR $1.02
- Average True Range (ATR)
- AEON 0.07
- MRKR 0.05
- MACD
- AEON -0.01
- MRKR -0.00
- Stochastic Oscillator
- AEON 31.38
- MRKR 49.33
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.